Healthcare Services Industry Overview

Direct-to-consumer genetic testing involves the marketing of genetic tests directly to consumers through media such as radio, television, print adverts, and the internet, where customers can purchase the tests through online marketplaces and pharmacies. After purchasing a test kit, clients give the business a DNA sample and provide individuals access to their genetic data without necessarily requiring the involvement of a healthcare professional or health insurance provider via a secure website, app, or written report with their results. The main types of direct-to-consumer (DTC) genetic testing include carrier testing, predictive testing, ancestry and relationship testing, nutrigenomic testing and other types. Carrier screening is a type of genetic test that assesses whether or not a person carries an alteration in one of their genes for a certain genetic disorder. They are used to test saliva, urine and blood samples by using different technologies such as single nucleotide polymorphism chips whole genome sequencing and targeted analysis. They are conducted in different business models such as health planning model, comprehensive genome tests model, medical precision tests model and restricted trait tests model and for use by various end-users including laboratories, blood banks, nursing homes, hospitals, imaging centers, home care, cosmetics and others. The direct-to-consumer (DTC) genetic testing market research report is one of a series of new reports from The Business Research Company that provides direct-to-consumer (DTC) genetic testing market statistics, including direct-to-consumer (DTC) genetic testing industry global market size, regional shares, competitors with a direct-to-consumer (DTC) genetic testing market share, detailed direct-to-consumer (DTC) genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the direct-to-consumer (DTC) genetic testing industry. This direct-to-consumer (DTC) genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global direct-to-consumer (DTC) genetic testing market size is expected to grow from $1.35 billion in 2022 to $1.58 billion in 2023 at a compound annual growth rate (CAGR) of 16.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global direct-to-consumer (DTC) genetic testing market size is expected to grow to $2.81 billion in 2027 at a CAGR of 15.5%. The rising prevalence of diseases and disorders with genetic transmission capabilities is expected to propel the growth of the direct-to-consumer (DTC) genetic testing market going forward. Genetic disorder refers to an illness caused by changes (mutation) in a person's DNA and it includes single-gene, multifactorial and chromosomal disorders. Direct-to-consumer genetic testing promotes awareness of various genetic disorders that helps in making predictions about health and provides personalized information about an individual’s health, disease risk, and other traits, thus, helps in taking effective health and lifestyle decisions to reduce the disease risk. For instance, according to MedlinePlus, a US-based online information service provided by the United States National Library of Medicine, in 2021, syndrome A is identified in about 1 in 200,000 Americans each year and currently around 100,000 kids suffer from syndrome B, whereas, it is estimated that nearly 12,000 people died globally from syndrome C in 2020 and approximately 1% of people in the United States develop disorder D during their lifetimes. Furthermore, in February 2022, according to the World Health Organization (WHO), a Switzerland-based agency of the United Nations responsible for international public health, birth abnormalities cause 240,000 new-borns to pass away in the first 28 days of life each year and an additional 170,000 children between the ages of 1 month and 5 years die as a result of birth abnormalities which includes heart defects, neural tube defects, and Down syndrome (a genetic disorder). Therefore, the rising prevalence of diseases and disorders with genetic transmission capabilities is driving the growth of the direct-to-consumer (DTC) genetic testing market. Technological advancement is a key trend gaining popularity in the direct-to-consumer (DTC) genetic testing market. Major companies operating in the direct-to-consumer (DTC) genetic testing market are focused on developing technologically advanced solutions to sustain their position in the market. For instance, in March 2020, Superdrug Stores Plc, a UK-based health and beauty retailer, launched CircleDNA, an advanced home DNA test kit that uses next-generation sequencing (NGS) technology. The new technology is capable of offering whole-exome sequencing which measures 31 million DNA positions per person and can detect more than 90% of cancer mutations. Additionally, it provides test findings including cancer risk, illnesses, and brain health to discover actionable insights into their genetic blueprint which can be crucial for people and help them modify their lifestyles for the better. In March 2022, LetsGetChecked, a US-based virtual care company that offers at-home testing, telehealth services, and pharmacy capabilities acquired Veritas Genetics for an undisclosed amount. Through this acquisition, LetsGetChecked aims to utilize whole-genome sequencing to start a full lifecycle of personalized healthcare to provide the market's most complete range of health testing and care options. Veritas Genetics is a US-based biotechnology company for personal genomics. Major players in the direct-to-consumer (dtc) genetic testing market are 23andMe Holding Co., Ancestry.com LLC, Color Health Inc., EasyDNA, Full Genomes Corporation, Helix, Identigene LLC, Living DNA, MyHeritage Ltd., FamilyTreeDNA, Myriad Genetics Inc., Quest Diagnostics, Mapmygenome, Genesis HealthCare, Gene by Gene, Laboratory Corporation of America Holdings, Positive Bioscience, Sonora Quest Laboratories, Xcode Life Sciences Private Limited, 24Genetics, Konica Minolta Inc., Direct Laboratory Services LLC, Prenetics Global, Karmagenes, Pathway Genomics, Request A Test Ltd., Any Lab Test Now, Dante Labs, Fulgent Genetics, and Victorian Clinical Genetics Services. North America was the largest region in the direct-to-consumer (DTC) genetic testing market in 2022. Asia-Pacific was the second-largest region in the global direct-to-consumer (DTC) genetic testing market. The regions covered in the global direct-to-consumer (DTC) genetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the direct-to-consumer (DTC) genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The direct-to-consumer (DTC) genetic testing market includes revenues earned by entities by offering DTC genetic kits and services straight to end-customers, that are used in querying patients' DNA information. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global direct-to-consumer (DTC) genetic testing market is segmented - 1) By Type: Carrier Testing, Predictive Testing, Ancestry And Relationship Testing, Nutrigenomic Testing, Other Types 2) By Sample: Saliva, Urine, Blood 3) By Technology: Single Nucleotide Polymorphism Chips, Whole Genome Sequencing, Targeted Analysis 4) By Business Model: Health Planning Model, Comprehensive Genome Tests Model, Medical Precision Tests Model, Restricted Trait Tests Mode 5) By End User: Laboratories, Blood Banks, Nursing Homes, Hospitals, Imaging Centres, Home Care, Cosmetics, Other End-User

Online therapy service is the supply of expert mental fitness counselling via the internet, generally via live video chat, messaging app, email, or over the cell phone. Online counselling is a viable alternative to traditional in-person therapy and is rapidly gaining favor as a method of receiving mental health care. The main types of online therapy services include cognitive behavioral therapy, psychodynamic therapy and person-centered therapy. Cognitive behavioral therapy (CBT) is a form of psychological treatment that has been proven to be powerful for a range of troubles which includes melancholy, tension issues, alcohol and drug use troubles, marital troubles, consumption disorders, and intense intellectual contamination. The various tools used include email, mobile device apps, real-time instant messaging, telephone and video conferencing for applications in residential and commercial uses. The online therapy services market research report is one of a series of new reports from The Business Research Company that provides online therapy services market statistics, including online therapy services industry global market size, regional shares, competitors with an online therapy services market share, detailed online therapy services market segments, market trends and opportunities, and any further data you may need to thrive in the online therapy services industry. This online therapy services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global online therapy services market size is expected to grow from $7.67 billion in 2022 to $9.62 billion in 2023 at a compound annual growth rate (CAGR) of 25.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global online therapy services market size is expected to grow to $24.00 billion in 2027 at a CAGR of 25.7%. Increasing adoption of smartphones is expected to propel the growth of the online therapy service market going forward. Smartphone adoption is increasing mainly due to affordability, availability of quality devices and internet penetration. Smartphones or text messaging are used to deliver treatment for certain psychological conditions via wearable technology and digital apps such as mood trackers, coaching programs, and connected monitors, which help people successfully manage anxiety, build resilience, and become more in tune with their happiness. Mobile health applications can supplement existing treatments, such as counselling, or they can be used on their own as a less formal approach for users to take ownership of their well-being in blended healthcare, resulting in the growth of the online therapy services market. For instance, in September 2022, according to "UK mobile phone statistics 2022" by Uswitch Limited, a UK-based switching website, and pricing comparison service, there were 71.8 million mobile connections in the UK at the start of 2022 (4.2 million more than the UK population)—a 3.8% rise from 2021 (around 2.6 million). This is most likely because many persons will have more than one connection registered to them (i.e., personal and work phones). The UK population is expected to reach 68.3 million by 2025, with 95% (approximately 65 million people) owning a smartphone. Therefore, the increasing adoption of smartphones is driving the growth of the online therapy services market. Technological advancements are the key trend gaining popularity in the online therapy services market. Major companies operating in the online therapy services market are developing innovative technologies such as artificial intelligence-based chatbots, using machine learning for mental therapies and others to sustain their position in the market. For instance, in November 2021, Insight Healthcare, a UK-based non-profit corporation working on behalf of the National Health Service (NHS) for Improving Access to Psychological Therapies (IAPT) services partnered with Limbic AI, a UK-based AI-powered therapy assistance provider to launch an AI-powered therapy helper for carers, professionals, and patients. The new AI referral tool collects crucial information and determines if a person has mild or complicated symptoms, allowing patients with mild symptoms to obtain a more appropriate 20-minute assessment. By automating these early stages, the organization will save approximately 7,300 hours of therapist time every year. This will allow them to focus on getting more individuals the aid they need as quickly as possible. In February 2020, Wellin5 Innovations Inc., a Canada-based innovative online telehealth counselling platform aimed at improving the mental health of employees acquired Therachat for an undisclosed amount. The acquisition of Therachat broadens Wellin5's mental health expertise to include providing a full client and counsellor-centric experience on a centralized platform, a library of mobile health tools such as emotion tracking, thought reframing, mindfulness, and others, meaningful support through engagement and self-help mental health exercises. Therachat is a US-based mental health start-up that offers online therapy sessions. Major players in the online therapy services market are TalkSpace, BetterHelp, MDLive, Calmerry, 7 Cup, Regain, Breakthrough, Doctor on Demand, Amwell, Pride Counseling, Cerebral, SOC Telemed, HopeQure, Teladoc Health, Online-Therapy.com, ThriveTalk, and Teen Counseling. Asia-Pacific was the largest region in the online therapy services market in 2022. The regions covered in the global online therapy services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the online therapy services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The online therapy services market includes revenues earned by entities by providing dialectical behavior therapy, EMDR (eye movement desensitization and reprocessing) therapy and family therapy services virtually through the internet. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global online therapy services market is segmented - 1) By Type: Cognitive Behavioral Therapy, Psychodynamic Therapy, Personal Centered Therapy 2) By Tool: Email, Mobile Device Apps, Real-Time Instant Messaging, Telephone, Video Conferencing 3) By Application: Residential Use, Commercial

Prenatal DNA sequencing refers to a method of sequencing the DNA of an unborn baby by using the blood sample from the mother that helps to reveal the full genetic code of the unborn baby. It is used to detect fetal disorders or diseases. The main types of prenatal DNA sequencing are genetic diseases and nonhereditary diseases. Genetic diseases refer to any disorder or disease that is caused by mutations in one or more genes. DNA sequencing helps to determine whether a gene contains a mutation that causes a disorder. It is used in various applications such as hemophilia, down syndrome, cystic fibrosis, autism, DiGeorge syndrome, AIDS, cancer, and others by academic research, clinical research, hospitals and clinics, pharmaceutical and biotechnology companies, and other users. The prenatal DNA sequencing market research report is one of a series of new reports from The Business Research Company that provides prenatal DNA sequencing market statistics, including the prenatal DNA sequencing industry global market size, regional shares, competitors with a prenatal DNA sequencing market share, detailed prenatal DNA sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the prenatal DNA sequencing industry. This prenatal DNA sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global prenatal DNA sequencing market is expected to grow from $1.84 billion in 2022 to $2.09 billion in 2023 at a compound annual growth rate (CAGR) of 13.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The prenatal DNA sequencing market is expected to grow to $3.52 billion in 2027 at a CAGR of 13.9%. The increasing prevalence of cancer is expected to propel the growth of the prenatal DNA sequencing market going forward. Cancer refers to a disease in which a few body cells grow uncontrollably and spread to other parts. Prenatal DNA sequencing in cancer is used to detect fetal aneuploidy in maternal plasma and to identify cancer in the fetus. The sequencing reveals the inherited or germline DNA changes that raise a person's chance of developing cancer. For instance, according to Globocan, a Switzerland-based provider of a worldwide database of cancer incidence and mortality rates, in 2020, there were around 19.29 million new cancer cases, and the number of cancer cases in a 5-year span is estimated to be 50.55 million. Therefore, the prevalence of cancer is driving the prenatal DNA sequencing market. Product innovation is a key trend gaining popularity in the prenatal DNA sequencing market. Major companies operating in the market are focused on developing innovative solutions to strengthen their market position. For instance, in November 2022, Juno Diagnostics, Inc., a US-based health technology company that democratizes access to valuable genetic information, launched the noninvasive prenatal screening test "Hazel". The test is uniquely designed with no risk of miscarriage, and it can be performed as early as 9 weeks into pregnancy by using a small amount of blood. It screens the pregnancy for common genetic conditions caused by extra or missing chromosomes, such as Down syndrome, Edwards syndrome, and Patau syndrome. In November 2022, Myriad Genetics, Inc., a US-based provider of genetic testing and precision medicine acquired Gateway Genomics, LLC for an undisclosed amount. Myriad expects to expand and strengthen its portfolio of women's health products, as well as provide access to personalized genetic tests, with the combined resources of this acquisition. Gateway Genomics, LLC is a US-based personal genomics, and prenatal DNA company and a developer of consumer genetic tests. Major players in the prenatal dna sequencing market are Agilent Technologies Inc., BGI Group, F. Hoffmann-La Roche, Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., Genomic Health Inc., Myriad Genetics Inc., Invitae Corporation, PerkinElmer Inc., Macrogen Inc., Pacific Biosciences, Genewiz LLC, 10x Genomics Inc., Oxford Nanopore Technologies Limited, and Thermo Fisher Scientific Inc. North America was the largest region in the prenatal DNA sequencing market in 2022. The regions covered in the prenatal DNA sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the prenatal DNA sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The prenatal DNA sequencing market includes revenues earned by entities by providing services such as prenatal next-generation sequencing, whole genome sequencing, DNA extraction, DNA fragmentation, and data collection and sequence analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global prenatal DNA sequencing market is segmented - 1) By Type: Genetic Diseases, Nonhereditary Diseases 2) By Application: Hemophilia, Down Syndrome, Cystic Fibrosis, Autism, DiGeorgre Syndrome, AIDS (Acquired Immunodeficiency Syndrome), Cancer, Other Applications 3) By End User: Academic Research, Clinical Research, Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Other End Users

Community Oncology Services Market Definition

Community oncology services involve a private physician who does not work for a hospital or a medical institution. These are used for community welfare purposes. The community oncology services market consists of sales of community oncology services by entities (organizations, and partnerships) that provide efficient, patient-centered oncology care at lower costs to patients, health plans and community physicians. These community oncology clinics are near to home, based in a particular community area so people can easily access the services. The community oncology practice may be only a single oncologist, with one office and a support staff of physician extenders (a physician extender is a licensed health care provider (not a physician) that provides medical services performed by a physician such as physician assistants or nurse practitioners), nurses, pharmacists or pharmacy technicians and other staff.

Glycomics or glycobiology refers to the study of the structure, biosynthesis, and biology of saccharides (including sugar chains or glycans) that are widely distributed in nature. Glycans are researched in glycobiology for their structure, production, and biology. The major products of glycomics or glycobiology are enzymes, kits, reagents and chemicals, instruments, and carbohydrates. Enzymes refer to biological polymers that catalyze biochemical reactions. These are used in various applications such as drug discovery and development, disease diagnostics, and others, and these are used in academic research institutes, pharmaceutical, and biotechnology companies and clinical laboratories. The glycomics or glycobiology market research report is one of a series of new reports from The Business Research Company that provides glycomics or glycobiology market statistics, including glycomics or glycobiology industry global market size, regional shares, competitors with a glycomics or glycobiology market share, detailed glycomics or glycobiology market segments, market trends and opportunities, and any further data you may need to thrive in the glycomics or glycobiology industry. This glycomics or glycobiology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global glycomics or glycobiology market is expected to grow from $1.38 billion in 2022 to $1.60 billion in 2023 at a compound annual growth rate (CAGR) of 15.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The glycomics or glycobiology market is expected to reach $2.82 billion in 2027 at a CAGR of 15.2%. The increase in the demand for medicines for the treatment of several severe chronic diseases is expected to propel the growth of the glycomics or glycobiology market going forward. Chronic diseases are health problems that are usually long-term and can be controlled but not healed. A glycomics studies changes in glycosylation and its functions, that helps in the development of drugs and related medication for several severe chronic diseases. For instance, in 2022, according to Cancer Facts and Figures 2022-2024, a scientific paper by the American Cancer Society, there would be 22.5 million cancer (a chronic disease) survivors by 2032 and is projected to reach 26 million by 2040. Similarly, Keytruda, a drug used in cancer immunotherapy, became one of the selling drugs in 2020, with revenue accounting for $14.38 billion, an increase of 29.7% compared to 2019. Thus, the increase in the demand for medicines for the treatment of several severe chronic diseases drives the glycomics or glycobiology market. Investments in research and development activities are a key trend gaining popularity in Glycomics or Glycobiology market. Major research and development institutions are funding in research centers for glycobiology aiming for the research and development of Glycomics or Glycobiology. For instance, in August 2022, Griffith University, an Australia-based Institute for Glycomics, launched the ACRF International Centre for Cancer Glycomics with a $2.6 million ACRF grant, that is dedicated to achieving cancer glyco-code. This is a unique facility, with a better understanding of the glyco-code that lead to the translation of novel discoveries and clinical outcomes that would help cancer patients improve their lives. In January 2021, Neogen, a US-based food safety company providing testing solutions for the food industry, acquired Megazyme for an undisclosed amount. Through this acquisition, Neogen gained a Megazyme product line that would help strengthen its business relationships with major food producers and companies. Megazyme is an Ireland-based developer, and manufacturer of analytical solutions, including glycobiology enzyme products. Major players in the glycomics or glycobiology market are Water Corporation, Aligent Technologies, Bruker Corporation, Merck KgaA, New England Biolabs, Danaher Corporation, Shimadzu Corporation, ProZyme Inc., Takara Bio, S-BIO, Asparia Glycomics S.L, Lectenz Bio, Chemily Glycoscience, Z Biotech LLC, and RayBiotech. North America was the largest region in the glycomics or glycobiology market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomics or glycobiology report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the glycomics or glycobiology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The glycomics or glycobiology market includes revenues earned by entities by maintaining tissue structure, porosity, and integrity. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global glycomics or glycobiology market is segmented - 1) By Product: Enzymes, Kits, Reagents and Chemicals, Instruments, Carbohydrates 2) By Application: Drug Discovery and Development, Disease Diagnostics, Other Applications 3) By End-user: Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Clinical Laboratories

Cell harvesting is an essential unit operation that involves removing cells, cell fragments, and other soluble and insoluble impurities that are hazardous to subsequent chromatographic separation processes. It is an essential step in linking upstream monoclonal antibody synthesis to downstream purification. The main types of cell harvesting are manual cell harvesters and automated cell harvesters. Manual cell harvesters refer to medical device that is used to collect cells from a cell culture medium without utilizing any instrument and picking the cells manually. These are used by various end-users such as biotechnology and biopharmaceutical companies, research institutes and others, and are distributed through various distribution channels such as retail and direct tenders. The cell harvesting market research report is one of a series of new reports from The Business Research Company that provides cell harvesting market statistics, including the cell harvesting industry global market size, regional shares, competitors with a cell harvesting market share, detailed cell harvesting market segments, market trends and opportunities, and any further data you may need to thrive in the cell harvesting industry. This cell harvesting market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cell harvesting market is expected to grow from $9.44 billion in 2022 to $10.11 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%.The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cell harvesting market is expected to reach $12.86 billion in 2027 at a CAGR of 6.2%. Rising cases of chronic disease are expected to propel the growth of the cell harvesting market going forward. Chronic disease refers to health problems that persist for a year or longer and necessitate continuing medical care, restricting everyday activities, or both. The rising number of chronic diseases requires more research to find novel treatments for diseases that require cell-harvesting procedures for drug development. For instance, in September 2020, according to a study report issued by American Action Forum, chronic illness frequency and expenses are increasing in the United States. Chronic illness is anticipated to continue increasing as the illness incidence among children and young people increases. Chronic illness is a significant healthcare issue since it costs the US $3.7 trillion annually, or about 19.6% of the GDP, and is rising Therefore, rising cases of chronic disease drive the cell harvesting market. Technological advancements are a key trend gaining popularity in the cell harvesting market. Major players are concentrating their efforts on creating innovative technologies to sustain their position in the cell harvesting market. For instance, in September 2022, Thermo Fisher Scientific Inc., a US-based scientific manufacturing company, launched the DynaSpin™ Single-Use Centrifuge System based on DynaSpin technology. The technology is specially created to offer the best single-use answer for extensive cell culture collection and offer centrifugation for cell harvesting. The DynaSpin system helps biological producers achieve their sustainability targets while lowering overall production costs. This device delivers up to a six-fold decrease in material requirements, eliminating 70% of waste compared to conventional harvest systems by lowering the number of filters needed for harvesting for the production of biologics. In March 2020, Danaher Corporation, a US-based healthcare technology company, acquired the biopharmaceutical business of General Electric Company, known as Cytiva, for$21.4 billion. Through this acquisition, Danaher increases its product and service portfolio, which enables biomanufacturing to scale up quickly in order to meet patient demand. Cytiva is a US-based life science company pioneering in the discovery and development of innovative therapies for human health. Major players in the cell harvesting market are PerkinElmer Inc., Connectorate AG, Sartorius AG, Terumo Corporation, Cox Scientific Ltd., AVITA Medical Inc., Tomtec Inc., Teleflex Incorporated, Arthrex Inc., Antylia Scientific, Danaher Corporation, Bertin Technologies, Merck & Co Inc., Eurofins Scientific SE, Agilent Technologies Inc., Thomas Scientific Inc., and Pall Corporation. North America was the largest region in the cell harvesting market in 2022. The regions covered in the cell harvesting report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell harvesting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cell harvesting includes revenues earned by entities by centrifugation, filtration, and microfiltration. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cell harvesting market is segmented - 1) By Type: Manual Cell Harvesters, Automated Cell Harvesters 2) By End-Users: Biotechnology and Biopharmaceutical Companies, Research Institute, Other End-Users 3) By Distribution Channel: Retail, Direct Tenders

Glioblastoma multiforme (GBM) treatment refers to the management and care of a patient suffering from glioblastoma multiforme, a kind of brain or spinal cord tumor that grows quickly. Adults with this primary malignant brain tumor have the highest prevalence rate. The main treatment of glioblastoma multiforme (GBM) treatment are surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating field (ttf) therapy, and immunotherapy. Surgery is a field of medicine that focuses on using manual and instrumental methods to heal wounds, illnesses, and other ailments. The drugs types involved are emozolomide, bevacizumab, lomustine, carmustine wafers, and others that are administered by oral, parenteral, other routes of administration and used by hospitals, clinics, ambulatory surgical centers. The glioblastoma multiforme (GBM) treatment market research report is one of a series of new reports from The Business Research Company that provides glioblastoma multiforme (GBM) treatment market statistics, including glioblastoma multiforme (GBM) treatment industry global market size, regional shares, competitors with glioblastoma multiforme (GBM) treatment market share, detailed glioblastoma multiforme (GBM) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the glioblastoma multiforme (GBM) treatment industry. This glioblastoma multiforme (GBM) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global glioblastoma multiforme (GBM) treatment market is expected to grow from $2.04 billion in 2022 to $2.26 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The glioblastoma multiforme (GBM) treatment market is expected to grow to $3.26 billion in 2027 at a CAGR of 9.7%. The increasing prevalence of brain disorders is expected to propel the growth of the glioblastoma multiforme (GBM) treatment market going forward. Brain disorders refer to abnormal functioning of the brain as well as the nerves found throughout the human body and the spinal cord. The increasing prevalence of brain disorders such as glioblastoma multiforme (GBM) is due to various contributing factors such as the aging population, compromised immune systems, overdiagnosis, ionizing radiation, air pollution, and others which creates the need for the treatment of brain disorders to improve well-being. For instance, according to the report published by Globocan, a US-based international agency for providing global cancer statistics, approximately 308,102 cancer cases were detected for the brain and central nervous system, and 251,329 deaths in the year 2020 globally. Additionally, according to a report published by the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, in 2022, it is estimated around 25,050 malignant tumors of the brain or spinal cord cancer cases will be diagnosed in the US. Therefore, the increasing prevalence of brain disorders is driving the growth of the glioblastoma multiforme (GBM) treatment market. Advancements in therapies are a key trend gaining popularity in the glioblastoma multiforme (GBM) treatment market. Major companies operating in the market are focused on research and development for therapy innovations to sustain their position in the market. For instance, in November 2021, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company, launched DELYTACT, the first-ever oncolytic virus-based immunotherapy (Teserpaturev) in collaboration with the Institute of Medical Science, The University of Tokyo to treat malignant glioma. Oncolytic viruses refer to genetically modified viruses that are capable of infecting and specifically replicating in cancer cells, eventually causing cell death without damaging healthy cells to inhibit cell proliferation. The unique features of DELYTACT (Teserpaturev) provide patients with the ability to produce immune-boosting molecules or initiate anti-cancer immunity by triggering the multiple mechanisms of the patient’s immune system and also able to kill the tumor cells that have spread to other parts of the brain. In April 2022, Elekta, a Sweden-based company that provides radiation therapy, radiosurgery, related equipment, and clinical management for the treatment of cancer signed a global commercial collaboration agreement with GE Healthcare, a US-based manufacturer and distributor of diagnostic imaging agents and radiopharmaceuticals for imaging modalities used in medical imaging procedures. This agreement will be enabling them to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy. This partnership will allow the companies to jointly promote solutions for each cancer center’s needs. Major players in the glioblastoma multiforme (gbm) treatment market are Merck & Co Inc., F. Hoffmann-La Roche AG, Amgen Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Arbor Pharmaceuticals LLC, Amneal Pharmaceuticals Inc., Karyopharm Therapeutics, Sumitomo Pharma Oncology, Novartis AG, Carl Zeiss AG, Varian Medical Systems, Elekta, The Eckert & Ziegler Group, Accord Healthcare Limited, Angiochem Inc., ANI Pharmaceuticals, AstraZeneca plc., Cantex Pharmaceuticals Inc., Celon Laboratories Pvt. Ltd., Diffusion Pharmaceuticals Inc., EnGeneIC, ERC SA, Genenta Science, Jazz Pharmaceuticals Inc., Loxo Oncology Inc., Vascular Biogenics, Zydus Pharmaceuticals Inc., AbbVie, and Genentech Inc. North America was the largest region in the glioblastoma multiforme (GBM) treatment market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (GBM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the glioblastoma multiforme (GBM) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The glioblastoma multiforme (GBM) treatment market includes revenues earned by entities by performing neurological exams, imaging tests, surgical operations, radiotherapy, and molecular profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global glioblastoma multiforme (GBM) treatment market is segmented - 1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy 2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes 3) By Route of Administration: Oral, Parenteral, Other Route Of Administrations 4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers

Urgent care centers are similar to walk-in retail clinics that provide quick on-demand care, but instead of treating low-acuity disorders like bronchitis and mild infections, urgent care clinics are equipped to handle more serious problems like fractures, sprains, and wounds. The urgent care center services are trauma or injury services, vaccination services, acute illness treatment solutions, and others. Trauma care service is specialized medical care for those who have suffered bodily traumas. The ownerships involved are corporate-owned, hospital-owned, physician-owned, and others. The urgent care center market research report is one of a series of new reports from The Business Research Company that provides urgent care center market statistics, including urgent care center industry global market size, regional shares, competitors with urgent care center market share, detailed urgent care center market segments, market trends, and opportunities, and any further data you may need to thrive in the urgent care center industry. This urgent care center market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global urgent care center market is expected to grow from $22.88 billion in 2022 to $24.19 billion in 2023 at a compound annual growth rate (CAGR) of 5.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The urgent care center market is expected to grow to $30.13 billion in 2027 at a CAGR of 5.7%. Increasing chronic diseases is expected to propel the demand for the urgent care center market going forward. Chronic disease is ongoing, progresses, and usually gets worse over time if no lifestyle adjustments are undertaken. Alzheimer's disease, rheumatoid arthritis, Parkinson's disease, and cancer are all examples of chronic diseases. Chronic diseases require proper health care services and medications, increasing the need for urgent care centers. For instance, according to National Cancer Institute (NCI), a US-based federal government's principal agency for cancer research and training. In 2020, there were 1,806,590 new cases of cancer were diagnosed in the United States and 606,520 people died from the disease. Also by 2040, the number of new cancer cases per year is predicted to reach 29.5 million, with 16.4 million cancer-related deaths. By 2030, the number of cancer survivors is expected to reach 22.2 million. Therefore, increasing chronic diseases are driving the growth of the urgent care center market. Technological advancements are emerged as a key trend gaining popularity in the urgent care center market. Major companies operating in the urgent care center market are focused on developing new technologies to sustain their position in the market. For instance, in October 2020, Doctorlink, a UK-based health technology solutions provider launched an Urgent Care Triage platform for Accident and Emergency (A&E) departments. The new service will help patients receive the appropriate professional care for their symptoms more promptly, reducing long wait periods. According to research, 4 million accident and emergency visits each year are not clinically necessary. Non-urgent attendances, where symptoms and medical history indicate patients should see a general practitioner, pharmacist, or other community services, account for one-sixth of all accident and emergency visits each year. In July 2022, WellNow Urgent Care, a US-based physicians, and mental health specialists company acquired Physicians Immediate Care for an undisclosed amount. Through this acquisition, WellNow Urgent Care aims to expand its reach in the physicians and mental health category and enhance its customer base. Physicians Immediate Care is a US-based urgent care services company offering digital x-rays, lab work, physicals, immunizations, fracture care, and minor surgical procedures. Major players in the urgent care center market are NextCare Holdings Inc., Concentra Inc., HCA Healthcare, MedExpress Urgent Care, American Family Care, Fastmed Urgent Care, Carenow Healthcare Private Limited, St Joseph's Health Care London, U.S. HealthWorks Inc., Citymd Healthcare Private Limited, GoHealth Urgent Care, Columbia Asia, CareSpot, Dignity Health Care, United Health Group, International SOS, Texas MedClinic, Patient First, Aurora Urgent Care, Bellin Health, Doctors Care, MD Now Medical Centers Inc., and Intermountain InstaCare. North America was the largest region in the urgent care center market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urgent care center market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the urgent care center market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The urgent care centers market includes revenues earned by entities by providing physical examinations and immunization services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global urgent care center market is segmented - 1) By Service: Trauma or Injury Services, Vaccination Services, Acute Illness Treatment Solutions, Other Services 2) By Ownership: Corporate Owned, Hospital Owned, Physician Owned, Other Ownerships